Cnbc
@cnbc·4.2M subscribers·16.1K videos
Abbott Freestyle Libre 3 Review — A Discrete CGM For Diabetics
Posted
October 24, 2022
Views
1,349,717
Likes
4,306
Comments
459
Engagement
0.35%
October 24, 2022
1,349,717
4,306
459
0.35%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
Abbott Laboratories newest continuous glucose monitor is now available at participating retail pharmacies and through durable medical equipment suppliers. The Freestyle Libre 3 was approved by the FDA in June and is a step up from previous Abbott systems.
Abbott Laboratories and Dexcom are the leaders in the CGM market, which hit $5.1 billion in revenue in 2021 and is expected to reach $13.2 billion by 2028, according to Vantage Market Research. Abbott’s CGM systems, called FreeStyle Libre, generated $3.7 billion in revenue last year, with 4 million users globally.
CNBC's Erin Black, a type 1 diabetic, tested out the Libre 3 for over a month. Here is her review.
» Subscribe to CNBC
» Subscribe to CNBC TV
About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more.
Connect with CNBC News Online
Get the latest news
Follow CNBC on LinkedIn
Follow CNBC News on Facebook
Follow CNBC News on Twitter
Follow CNBC News on Instagram
#CNBC
Abbott Freestyle Libre 3 Review — A Discrete CGM For Diabetics
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
